NSE: EMCURE | BSE: 544210

Strong Performer, Getting Expensive

Download real time

1881.00 11.50 (0.62%)

Near 52W High of ₹1944.00

62,196 NSE+BSE Volume

NSE 24 Jul, 2026 3:31 PM (IST)

35,678.8

Market Cap

High in industry

Beta 1Year

Very Low volatility

Emcure Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMCURE, BSE:544210 Emcure Pharmaceuticals Ltd.

Search Inside the pdf :

Emcure Pharmaceuticals Ltd.

20 Jul 2026

1881.00

0.62%

A multi-engine growth story

Buy: Emcure Pharmaceuticals Ltd.

Motilal Oswal

Since its inception in 1981, Emcure Pharmaceuticals (Emcure) has evolved into an R&D-driven diversified pharma franchise with a meaningful global scale built over the past decade through calibrated organic and inorganic investments across markets, platforms and capabilities.

Motilal Oswal released a Buy report for Emcure Pharmaceuticals Ltd. with a price target of 2260.0 on 20 Jul, 2026.

Emcure Pharmaceuticals Ltd.

06 May 2026

1881.00

0.62%

Emcure Pharma (BUY): In-line Earnings; all growth drivers intact

Buy: Emcure Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT grew by 1.5%/0.4%-1.1% above our estimates, while EBITDA Margin was 22 bps below our estimates

Emcure Pharmaceuticals Ltd. is trading above all available SMAs

Emcure Pharmaceuticals Ltd.

05 Feb 2026

1881.00

0.62%

Emcure Pharma (BUY): Scaling Europe through long tail growth

Buy: Emcure Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT was 6%/7%/-6% above our estimates. APAT was 6% above estimates. EBITDA margin was 16 bps above estimates

Emcure Pharmaceuticals Ltd. is trading above all available SMAs

Emcure Pharmaceuticals Ltd.

05 Dec 2025

1881.00

0.62%

Emcure Pharma (BUY): Margin increment to increase return ratios

Buy: Emcure Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

We hosted Mr. Vikas Thapar (President) and Mr. Piyush Nahar (IR Head) virtually. The duo expressed enthusiasm over Poviztra brand

Emcure Pharma has gained 22.88% in the last 6 Months

Emcure Pharmaceuticals Ltd.

12 Nov 2025

1881.00

0.62%

Emcure Pharma (BUY): In-line earnings; stable growth across geographies

Buy: Emcure Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 1.2%/2.7%/8.2% higher than our estimates. EBITDA margin was reported 28 bps higher, at 19.3%

Emcure Pharmaceuticals Ltd. is trading above all available SMAs

Emcure Pharmaceuticals Ltd.

01 Oct 2025

1881.00

0.62%

[Initiation] Emcure Pharma (BUY): Immune to US tariff woes

Buy: Emcure Pharmaceuticals Ltd.

BOB Capital Markets Ltd.

Domestic business is expected to recover with increasing traction from Sanofi's portfolio, leading to growth higher than IPM

Emcure Pharmaceutica.. has an average target of 2112.50 from 2 brokers.

Emcure Pharmaceuticals Ltd.

03 Jul 2024

1881.00

0.62%

EMCURE PHARMACEUTICAL LIMITED

IPO Subscribe: Emcure Pharmaceuticals Ltd.

Hem Securities

Emcure Pharma has gained 31.96% in the last 1 Year

Emcure Pharmaceuticals Ltd.

02 Jul 2024

1881.00

0.62%

IPO Note-Emcure Pharmaceuticals Limited-03072024

IPO Note: Emcure Pharmaceuticals Ltd.

HDFC Securities

Issue Snapshot: Issue Open: July 03 July 05, 2024 Price Band: Rs. 960 1008 (Discount of Rs 90 per sh for all eligible employees) *Issue Size: Up to Rs 1952.0 cr (Fresh issue up to Rs 800 cr + Offer for sale of up to 11,428,839 eq sh including employee reservation of upto 108,900 eq sh) Reservation for: QIB upto 50% eq sh Non-Institutional atleast 15% eq sh ((including 1/3rd for applications between Rs.2 lakhs to Rs.10 lakhs)) Retail atleast 35% eq sh Face Value: Rs 10 Book value: Rs 163.22 (March 31, 2024) Bid size: - 14 equity shares and in multiples thereof 100% Book built Issue IPO Note-Emcure Pharmaceuticals Limited-03072024